ABATE, Maria Lorena
 Distribuzione geografica
Continente #
NA - Nord America 9.003
EU - Europa 7.438
AS - Asia 5.321
AF - Africa 213
SA - Sud America 187
OC - Oceania 145
Continente sconosciuto - Info sul continente non disponibili 14
Totale 22.321
Nazione #
US - Stati Uniti d'America 8.648
CN - Cina 3.186
IT - Italia 1.347
DE - Germania 1.285
SE - Svezia 987
IE - Irlanda 590
FR - Francia 554
UA - Ucraina 392
JP - Giappone 376
GB - Regno Unito 323
RU - Federazione Russa 305
FI - Finlandia 278
KR - Corea 255
CA - Canada 246
PL - Polonia 246
SG - Singapore 242
AT - Austria 231
IN - India 228
TR - Turchia 221
VN - Vietnam 221
DK - Danimarca 159
TW - Taiwan 156
HK - Hong Kong 154
GR - Grecia 150
AU - Australia 142
ES - Italia 125
BR - Brasile 109
NL - Olanda 108
EG - Egitto 96
MX - Messico 92
BE - Belgio 67
ID - Indonesia 55
CH - Svizzera 47
NO - Norvegia 43
IR - Iran 41
RO - Romania 41
PT - Portogallo 34
CZ - Repubblica Ceca 33
PK - Pakistan 29
MU - Mauritius 23
TH - Thailandia 23
CO - Colombia 22
KE - Kenya 22
HU - Ungheria 21
MY - Malesia 21
SA - Arabia Saudita 21
IL - Israele 19
PH - Filippine 17
HR - Croazia 16
EU - Europa 14
UZ - Uzbekistan 14
AR - Argentina 13
IQ - Iraq 13
CL - Cile 12
PE - Perù 11
SI - Slovenia 11
BG - Bulgaria 10
RS - Serbia 10
VE - Venezuela 10
ZA - Sudafrica 10
EC - Ecuador 8
ET - Etiopia 8
ZM - Zambia 8
CM - Camerun 7
BF - Burkina Faso 6
BY - Bielorussia 6
CV - Capo Verde 6
CU - Cuba 5
MN - Mongolia 5
NG - Nigeria 5
AE - Emirati Arabi Uniti 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
CR - Costa Rica 3
GH - Ghana 3
KZ - Kazakistan 3
LV - Lettonia 3
MZ - Mozambico 3
NZ - Nuova Zelanda 3
SD - Sudan 3
YE - Yemen 3
CI - Costa d'Avorio 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
GM - Gambi 2
GT - Guatemala 2
LU - Lussemburgo 2
MA - Marocco 2
MD - Moldavia 2
MK - Macedonia 2
PS - Palestinian Territory 2
QA - Qatar 2
SR - Suriname 2
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
CD - Congo 1
DO - Repubblica Dominicana 1
Totale 22.310
Città #
Chandler 1.081
Beijing 981
Ann Arbor 763
Dublin 582
Fairfield 563
Ashburn 405
Houston 371
Redwood City 343
Shanghai 299
Wilmington 295
Woodbridge 293
Villeurbanne 279
Dearborn 276
Torino 260
Jacksonville 230
Nyköping 219
Seattle 211
Guangzhou 205
Vienna 204
Pisa 194
Medford 185
Princeton 174
Cambridge 166
Warsaw 140
Singapore 138
Ottawa 137
Fremont 131
Dong Ket 117
Nanjing 103
Hangzhou 100
Wuhan 93
New York 90
Tokyo 87
Taipei 84
Chengdu 83
West Jordan 79
Boston 69
Rome 69
Turin 63
Boardman 56
Istanbul 51
Hefei 49
Milan 48
London 46
Zhengzhou 44
Brussels 43
Toronto 43
Munich 42
San Diego 41
Seoul 41
Sydney 41
Chongqing 40
Norwalk 39
Jinan 36
Los Angeles 36
Düsseldorf 35
Kunming 35
Washington 35
Central 33
Pune 33
Ankara 32
Shenyang 32
Tianjin 32
Hanoi 31
Helsinki 31
Changchun 30
Duncan 29
Central District 28
Jakarta 27
Cairo 26
Changsha 26
San Mateo 26
Amsterdam 24
Naples 23
Hong Kong 22
Berlin 21
Bucharest 21
Delhi 21
Silver Spring 21
Stavanger 21
Phoenix 20
Falls Church 19
Frankfurt am Main 19
Paris 19
Melbourne 18
Moscow 18
Nürnberg 18
Fuzhou 17
Hebei 17
Qingdao 17
Rochester 17
São Paulo 17
Barcelona 16
Copenhagen 16
Nanchang 16
Nanning 16
Xian 16
Athens 15
Bengaluru 15
Bologna 15
Totale 11.894
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.687
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 968
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 926
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 876
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 635
FibroGENE: A gene-based model for staging liver fibrosis 510
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 493
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 431
Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin for hepatocellular carcinoma detection 351
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 348
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 344
Chronic hepatitis B therapy: available drugs and treatment guidelines. 325
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 301
Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. 261
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 258
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis 244
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 242
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 212
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B 189
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 188
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 185
Serum heat shock protein 27 is a new circulating biomarker for hepatocellular carcinoma 183
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 168
The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B 164
Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. 159
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 158
ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. 157
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 155
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 147
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 145
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 139
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 137
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 135
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. 134
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. 134
'e' antigen defective hepatitis B virus and course of chronic infection. 131
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 131
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 129
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 127
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 127
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 127
Antibodies against GOR in patients undergoing orthotopic liver trasplantation (OLT) 126
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 126
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Italian blood donors with anti-HBc and occult hepatitis B virus infection 124
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. 124
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 123
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 122
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 122
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 121
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort 116
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 115
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 114
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 113
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 113
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 113
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence 112
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 112
CLINIC EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HBV CHRONIC INFECTION 111
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. 109
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 108
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 107
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 106
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 106
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 104
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 104
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 103
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 103
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 103
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 103
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 103
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 102
Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. 102
CLINICAL EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HBV INFECTION 101
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 101
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 100
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 99
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 99
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C 99
Liver transplant for viral hepatitis. Recurrence of reinfection 98
Inactive hepatitis B virus carriers: a favourable clinical condition 97
la reinfezione virale nel post -trapianto 97
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 97
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 96
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 94
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 94
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 94
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 93
Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. 89
Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease 89
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 88
Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor 87
Serological characterization of occult HBV infection in liver donors 87
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 87
Prevalence of hepatitis C virus/hepatitis G virus co-infection in Turin: updated data ten years later. 85
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 85
Totale 19.178
Categoria #
all - tutte 51.239
article - articoli 0
book - libri 0
conference - conferenze 17.021
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.260


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.045 145 101 151 321 220 506 289 241 335 341 202 193
2020/20213.122 243 308 190 214 310 243 253 164 282 278 254 383
2021/20223.846 180 212 176 384 309 239 341 346 236 446 560 417
2022/20233.931 354 312 164 323 317 768 318 293 397 210 245 230
2023/20243.130 308 342 218 246 216 408 180 307 62 292 227 324
2024/202592 92 0 0 0 0 0 0 0 0 0 0 0
Totale 23.060